Welcome to our dedicated page for Neuronetics news (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics stock.
Neuronetics, Inc. (NASDAQ: STIM) is a pioneering medical technology company renowned for its NeuroStar Advanced Therapy System, which uses transcranial magnetic stimulation (TMS) to treat psychiatric and neurological disorders. Headquartered in Malvern, PA, Neuronetics has established itself as a leading force in the non-invasive treatment of major depressive disorder (MDD), particularly for patients who have not found relief from standard antidepressant medications.
The company's flagship product, the NeuroStar Advanced Therapy System, is FDA-cleared for the treatment of MDD in adults and approved for additional indications, including obsessive-compulsive disorder (OCD) and anxious depression in patients exhibiting comorbid anxiety symptoms. Notably, NeuroStar recently received FDA clearance to treat adolescents aged 15-21, making it the first TMS therapy to be approved for this age group. This expanded clearance has significantly increased Neuronetics' market potential, addressing an underserved segment of the population.
Neuronetics continues to make strides in both product development and market reach. The recent advancements in their TrakStar® Patient Data Management System have enhanced the way healthcare providers manage and document patient treatment, improving workflow and patient outcomes. Furthermore, the company has forged strategic partnerships, such as the five-year exclusive agreement with Transformations Care Network, facilitating greater access to NeuroStar TMS across multiple states.
The company's commitment to enhancing mental health treatment accessibility is evident through its proactive health policy advocacy. Neuronetics is the only TMS company with a dedicated health policy team, actively working with providers and payors to update coverage criteria. This effort has yielded favorable changes in insurance coverage, making TMS therapy more accessible to those in need.
Financially, Neuronetics has shown promising growth. In the fourth quarter of 2023, the company reported a 12% increase in total revenue, driven primarily by an uptick in NeuroStar treatment session sales. The gross margin improved to 77.6%, bolstered by strong revenue growth and efficient expense management. The company's strategic initiatives, including the Better Me Guarantee Provider Program, aim to further enhance patient care and treatment accessibility. With a robust pipeline of projects and ongoing financial improvements, Neuronetics is well-positioned for sustained growth and innovation in the mental health sector.
Neuronetics (NASDAQ: STIM) announced the publication of clinical data from its NeuroStar Outcomes Registry in the Journal of Affective Disorders, suggesting that NeuroStar Advanced Therapy may be considered a first-line treatment for Major Depressive Disorder (MDD). The registry, launched in 2016, includes data from over 5,000 patients and indicates robust antidepressant effects. Key findings show high response (58%) and remission (37%) rates, along with favorable outcomes in females. The research underscores NeuroStar's efficacy and safety in treating treatment-resistant depression during the COVID-19 pandemic.
Neuronetics (NASDAQ: STIM) announced the appointment of Sara Grubbs as Vice President of Sales, effective immediately, bringing 15 years of medical device experience. Grubbs aims to enhance NeuroStar Advanced Therapy's market presence, particularly for treating Major Depressive Disorder. The company also revealed the departure of Dan Guthrie, the Chief Commercial Officer, by year's end. A restricted stock grant of 75,000 shares was approved for Grubbs, contingent on her employment. This change comes as Neuronetics seeks growth opportunities in the psychiatric treatment market.
Neuronetics, a commercial-stage medical technology company, is promoting its NeuroStar Advanced Therapy for depression during National Depression Awareness Month. Over 300 practices nationwide are offering free consultations to educate patients about non-drug treatment options. Depression affects over 16.1 million adults in the U.S., with many not finding relief from traditional medications. The COVID-19 pandemic has increased depression rates, amplifying the need for alternative treatments like NeuroStar, which uses magnetic pulses to aid patients.
Neuronetics is set to share key clinical data on its NeuroStar® Advanced Therapy during the Clinical TMS Society's virtual events. The data includes a pilot study on bipolar depression and findings from the largest patient registry for Major Depressive Disorder (MDD) treatment. Upcoming sessions include a product theater webinar on September 29, where results from a prospective trial on bipolar depression will be discussed. Neuronetics continues to innovate in depression treatment, emphasizing TMS's efficacy as a non-drug option.
Neuronetics, Inc. (NASDAQ: STIM) reported Q2 2020 revenues of $9.7 million, a 41% decrease from $16.6 million in Q2 2019, primarily due to COVID-19 impacts. Operating expenses fell 25% to $14.3 million. As of June 30, 2020, cash and cash equivalents totaled $54 million. The installed base grew 15% to 1,122 systems. The company received favorable reimbursement changes from major payers, potentially enhancing access to its NeuroStar therapy. Despite negative trends, management remains optimistic about recovery in the latter half of the year.
Neuronetics, Inc. (NASDAQ: STIM) announced the hiring of Keith J. Sullivan as President and CEO on July 14, 2020. In connection with this appointment, the Board of Directors approved significant long-term equity incentives for Sullivan. These include 500,000 restricted stock units (25% vesting annually), 500,000 performance restricted stock units (vesting based on stock price appreciation), and 1,000,000 non-qualified stock options with an exercise price of $1.98. This decision aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to incentivize leadership.
Neuronetics, Inc. (NASDAQ: STIM) has appointed Keith J. Sullivan as President and CEO, effective immediately, marking a significant leadership change. Sullivan brings over 30 years of experience in the medical device industry, having previously served in executive roles at ZELTIQ Aesthetics and other notable companies. The Board believes his background in commercializing medical products aligns well with Neuronetics' mission to enhance patient care in psychiatric disorders. The transition comes as the company aims to optimize its strategy and drive innovation amid increasing mental health challenges exacerbated by the COVID-19 pandemic.
Neuronetics (NASDAQ: STIM) has appointed Keith J. Sullivan as President and CEO, effective immediately. Sullivan brings over 30 years of experience in the medical device industry, having previously held leadership roles at ZELTIQ Aesthetics and others. The Board is confident in his ability to drive innovation and market growth. Sullivan emphasized the importance of mental health, especially during the COVID-19 pandemic, and aims to enhance the company's go-to-market strategy. The transition follows a successful interim leadership period, with gratitude expressed to the outgoing executive team.
FAQ
What is the current stock price of Neuronetics (STIM)?
What is the market cap of Neuronetics (STIM)?
What does Neuronetics, Inc. specialize in?
What is the NeuroStar Advanced Therapy System?
Is NeuroStar therapy FDA-approved?
How does NeuroStar therapy work?
What recent advancements has Neuronetics made?
How is Neuronetics improving access to mental health treatments?
What is the Better Me Guarantee Provider Program?
How has Neuronetics performed financially?
What is the company's approach to mental health?
How can I contact Neuronetics for support?
